Damian M. Mikulski

Mazowiecka 15 Street
Lodz, LD 92215, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation.

Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation.

Journal: British journal of haematology

Published: May 14, 2026

TLR7 polymorphisms are associated with COVID-19 susceptibility and severity.

TLR7 polymorphisms are associated with COVID-19 susceptibility and severity.

Journal: Frontiers in immunology

Published: March 23, 2026

Evaluation of mTOR, NFκB and BCL-2 Inhibitor Activity In Vitro in Karpas 1106P, a Primary Mediastinal B-Cell Lymphoma Cell Line.

Evaluation of mTOR, NFκB and BCL-2 Inhibitor Activity In Vitro in Karpas 1106P, a Primary Mediastinal B-Cell Lymphoma Cell Line.

Journal: Hematology reports

Published: January 08, 2026

Evaluation of mTOR, NFκB, and BCL-2 Inhibitor Activity In Vitro on Diffuse Large B-Cell Lymphoma Cells.

Evaluation of mTOR, NFκB, and BCL-2 Inhibitor Activity In Vitro on Diffuse Large B-Cell Lymphoma Cells.

Journal: Current issues in molecular biology

Published: December 28, 2025

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Journal: The Lancet. Haematology

Published: November 21, 2025

Serum citrulline as a prognostic marker in patients with oropharyngeal carcinoma treated with chemoradiotherapy.

Serum citrulline as a prognostic marker in patients with oropharyngeal carcinoma treated with chemoradiotherapy.

Journal: Contemporary oncology (Poznan, Poland)

Published: November 15, 2025

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Journal: Blood cancer journal

Published: November 04, 2025

Circulating microRNAs as prognostic biomarkers in patients with oropharyngeal cancer undergoing radiotherapy: temporal dynamics analysis.

Circulating microRNAs as prognostic biomarkers in patients with oropharyngeal cancer undergoing radiotherapy: temporal dynamics analysis.

Journal: Clinical and experimental medicine

Published: August 26, 2025

Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis.

Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis.

Journal: Leukemia research reports

Published: April 21, 2025

Primary Renal Lymphoma: Report of 32 Cases-A Retrospective Multicenter PLRG Analysis.

Primary Renal Lymphoma: Report of 32 Cases-A Retrospective Multicenter PLRG Analysis.

Journal: Biomedicines

Published: January 27, 2025

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.

Journal: The Lancet. Haematology

Published: January 16, 2025

Predictors and Profile of Severe Infectious Complications in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens: A Machine Learning Model for Pneumonia Risk.

Predictors and Profile of Severe Infectious Complications in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens: A Machine Learning Model for Pneumonia Risk.

Journal: Cancers

Published: September 09, 2024

Showing 1-12 of 39

Last Updated: 09/26/2026